24/7 Market News Snapshot 30 April, 2025 – Purple Biotech Ltd. American Depositary Shares (NASDAQ:PPBT)

April 30, 2025

DENVER, Colo., 30 April, 2025 (www.247marketnews.com) – (NASDAQ:PPBT) are discussed in this article.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is experiencing a notable surge in its stock value, currently trading at $2.881, up by 13.84% from the previous close of $2.531, during a lively pre-market session marked by trading volume of 603.02K shares. This upward momentum appears to be driven by heightened investor interest, potentially catalyzed by the company’s recent positive developments.

In a major breakthrough, Purple Biotech has released compelling data from its Phase 2 study of CM24, presented at the American Association of Cancer Research (AACR 2025). The study, titled “Final analysis of the randomized Phase 2 cohort of CM24 with nivolumab and chemotherapy,” showcased significant efficacy results, particularly among patients with advanced pancreatic cancer. Notably, the results revealed a remarkable 78% reduction in the risk of death and a striking 90% reduction in one patient subgroup characterized by high tumor CEACAM1 expression and low PD-L1 combined positive score.

These findings illustrate a substantial advancement in treatment for pancreatic ductal adenocarcinoma (PDAC), a cancer known for its dire prognosis and limited therapeutic options. CM24, a novel humanized monoclonal antibody, acts against the CEACAM1 protein, enhancing treatment effectiveness when used alongside nivolumab and standard chemotherapy protocols.

CEO Gil Efron expressed optimism regarding the biomarker-driven results, emphasizing their potential to shape future treatment strategies. The analysis encompassed data from a well-tolerated cohort of 31 patients, revealing substantial improvements across key metrics including overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and disease control rates (DCR).

With the emerging potential of CEACAM1 as a predictive biomarker in serum and tumor evaluations, Purple Biotech is poised to advance its clinical efforts and address critical unmet needs in oncology. Further information on the groundbreaking findings is available on the company’s website.

Related news for (PPBT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.